Clinical Trial Update: Study to Assess Safety and Efficacy of Treating Symptomatic, Ischemic, Chronic Congestive Heart Failure Patients with an LVEF of ≤40% with Fresh, Uncultured, Autologous, Adipose-derived Regenerative Cells Isolated from Lipoaspirate. [Phase 2]

View source ↗

Summary

Phase 2 study assessing safety and efficacy of fresh, uncultured autologous adipose-derived regenerative cells for symptomatic ischemic heart failure with LVEF …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Heart Failure

Drugs mentioned

• Fresh, Uncultured Autologous Adipose-Derived Regenerative Cells

Snippet

Sponsor: Ralf Rothoerl | Conditions: Myocardial Injury, LV Dysfunction | Phase 2 | Status: RECRUITING